Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant pembrolizumab with or without V940 in resectable non-small cell lung cancer without pathological complete response after neoadjuvant chemoimmunotherapy
2023-506327-29-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- May 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial of intismeran autogene and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co. Primary endpoint: Disease-free survival. Planned start May 2025; status: authorised.
02
Drugs
intismeran autogenepembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-506327-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506327-29-00.